Zyne, +4.92% Closed Upon Mondayand Was Up Slightly In After Market Trading Closing At $19.62.zynerba Pharmaceuticals Last Week Announced That It Has Completed Enrollment In The Phase 2 Star 1 (synthetic Transdermal Cannabidiol For The Treatment Of Epilepsy) Clinical Trial Evaluating Zyn002 Cannabidiol (cbd) Gel In Adult Epilepsy Patients With Refractory Focal Seizures.

Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing Medical marijuana commercial products. Zynerba Pharmaceuticals, Inc. ZYNE, +4.92% closed upon Mondayand was up slightly in after market trading closing at $19.62.Zynerba Pharmaceuticals last week announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. The company also announced that enrollment has completed in the Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis. Terra Tech Corp. (otcqx:TRTC) closed up over 5%on Mondayat $0.287 trading over 2.7 million shares by the market close.Terra Tech is in the final stages of designing a state-of-the-art cultivation facility projected to produce over one metric ton of premium grade cannabis per annum for its IVXX brand. Cannabics Pharmaceuticals Inc. (otcqb:CNBX) closed up over 12%on Mondayat $2.7199 trading over 500,000 shares by the market close.Cannabics Pharmaceuticals is dedicated to the development of personalized anti-cancer and palliative treatments. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. Cannabics Pharmaceutical’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.

To read more visit http://www.marketwatch.com/story/medicinal-cannabis-applications-target-the-development-of-enhanced-therapies-and-treatments-for-various-health-disorders-2017-03-21

Share This Post

Recent Articles

Leave a Reply